The enemy within: Keeping self-reactive T cells at bay in the periphery

Nature Reviews Immunology

Volumn 2, Issue 1, 2002, Pages 11-19

  Walker, Lucy S K ^a   Abbas, Abul K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN;

ACTIVATION INDUCED CELL DEATH; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL DEATH; CLONAL ANERGY; DENDRITIC CELL; GENE CONTROL; HUMAN; IMMUNITY; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; MICROORGANISM; NONHUMAN; PERIPHERAL TOLERANCE; PHENOTYPE; PHENOTYPE SKEWING; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; THYMUS; ANIMAL; APOPTOSIS; BIOLOGICAL MODEL; CYTOLOGY; GENETICS; IMMUNOLOGY; INFECTION;

ANIMALS; APOPTOSIS; AUTOANTIGENS; AUTOIMMUNITY; CLONAL ANERGY; DENDRITIC CELLS; HUMANS; INFECTION; MODELS, IMMUNOLOGICAL; PHENOTYPE; SELF TOLERANCE; T-LYMPHOCYTES;

EID: 0036360019     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri701     Document Type: Review

References (103)

1. Arstila, T. P. et al. A direct estimate of the human αβT cell receptor diversity. Science 286, 958-961 (1999).
2. Mason, D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol. Today 19, 395-404 (1998).
3. Derbinski, J., Schulte, A., Kyewski, B. & Klein, L. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nature Immunol. 2, 1032-1039 (2001).
4. Lohmann, T., Leslie, R. D. & Londei, M. T cell clones to epitopes of glutamic acid decarboxylase 65 raised from normal subjects and patients with insulin-dependent diabetes. J. Autoimmun. 9, 385-389 (1996).
5. Semana, G., Gausling, R., Jackson, R. A. & Hafler, D. A. T cell autoreactivity to proinsulin epitopes in diabetic patients and healthy subjects. J. Autoimmun. 12, 259-267 (1999).
6. Bouneaud, C., Kourilsky, P. & Bousso, P. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 13, 829-840 (2000).
7. Alferink, J. et al. Control of neonatal tolerance to tissue antigens by peripheral T cell trafficking. Science 282, 1338-1341 (1998).
8. Zinkernagel, R. M. Immunology taught by viruses. Science 271, 173-178 (1996).
9. Kurts, C., Miller, J. F., Subramaniam, R. M., Carbone, F. R. & Heath, W. R. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction J. Exp. Med. 188, 409-414 (1998).
10. Hoglund, P. et al. Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J. Exp. Med. 189, 331-339 (1999). Pancreatic, but not renal, antigen presentation is compromised in juvenile mice, probably explaining the delay in onset of disease in diabetes-prone mouse strains.
11. Andre, I. et al. Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc. Natl Acad. Sci. USA 93, 2260-2263 (1996).
12. Jenkins, M. K. & Schwartz, R. H. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165, 302-319 (1987).
13. + T cells from tolerance induction by the superantigen staphylococcal enterotoxin B. Eur. J. Immunol. 26, 858-862 (1996).
14. Krummel, M. F. & Allison, J. P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459-465 (1995).
15. Walunas, T. L., Bakker, C. Y. & Bluestone, J. A. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 183, 2541-2550 (1996).
16. Perez, V. L. et al. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6, 411-417 (1997).
17. Walunas, T. L. & Bluestone, J. A. CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J. Immunol. 160, 3855-3860 (1998).
18. Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541-547 (1995).
19. Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985-988 (1995).
20. Lechner, O. et al. Fingerprints of anergic T cells. Curr. Biol. 11, 587-595 (2001).
21. Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo, T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141-151 (1999). Mice on a C57/BL6 background that lack PD-1 exhibit glomerulonephritis and arthritis that is exacerbated if the Fas pathway is also defective. Lymphocytic infiltration of multiple organs is observed in 2C TCR transgenic mice that lack PD1.
22. Nishimura, H. et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291, 319-322 (2001).
23. Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034 (2000).
24. Latchman, Y. et al. PD-L2 is a second ligand for PD-I and inhibits T cell activation. Nature Immunol. 2, 261-268 (2001).
25. Chambers, C. A. The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol. 22, 217-223 (2001).
26. + OVA-specific TCR transgenic T cells persist in vivo for several months following tolerogenic administration of soluble OVA peptide.
27. H2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis. J. Immunol. 164, 3563-3572 (2000).
28. H2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes. J. Immunol. 162, 2511-2520 (1999).
29. H2) T cells induce acute pancreatitis and diabetes in immune-compromised nonobese diabetic (NOD) mice. J. Exp. Med 186, 299-306 (1997).
30. H2 bias. Neuroimmunol. 100, 64-73 (1999).
31. Chensue, S. W. et al. Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in CC chemokine receptor 8 knockout mice. J. Exp. Med. 193, 573-584 (2001).
32. Kearney, E. R., Pape, K. A., Loh, D. Y. & Jenkins, M. K. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1, 327-339 (1994).
33. Walker, L. S. et al. Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXC chemokine receptor 5-positive CD4 cells and germinal centers. J. Exp. Med. 190, 1115-1122 (1999)
34. Ansel, K. M., McHeyzer-Williams, L. J., Ngo, V. N., McHeyzer-Williams, M. G. & Cyster J. G. In vivo-activated CD4 T cells upregulate CXC chemokine receptor 5 and reprogram their response to lymphoid chemokines. J. Exp. Med. 190, 1123-1134 (1999).
35. Luther, S. A., Lopez, T., Bai, W., Hanahan, D. & Cyster J. G. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 12, 471-481 (2000).
36. + dendritic cells in murine lupus and preferential chemotaxis of B1 cells towards BLC. J. Exp. Med. 193, 1393-1402 (2001).
37. Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A. & Nagata, S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356, 314-317 (1992). First direct evidence for a non-redundant role of the Fas pathway in maintaining self-tolerance.
38. Sobel, E. S., Kakkanaiah, V. N., Cohen, P. L. & Eisenberg, R. A. Correction of gld autoimmunity by co-infusion of normal bone marrow suggests that gld is a mutation of the Fas ligand gene. Int. Immunol. 5, 127-1278 (1993).
39. Suda, T., Takahashi, T., Golstein, P. & Nagata, S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75, 1169-1178 (1993).
40. Fisher, G. H. et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81, 935-946 (1995).
41. Suzuki, A. et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14, 523-534 (2001).
42. Chen, W. et al. Requirement for transforming growth factor β1 in controlling T cell apoptosis. J. Exp. Med. 194, 439-454 (2001).
43. Lenardo, M. J. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis. Nature 353, 858-861 (1991).
44. Van Parijs, L. et al. Functional responses and apoptosis of CD25 (IL-2Rα)-deficient T cells expressing a transgenic antigen receptor. J. Immunol. 158, 3738-3745 (1997).
45. Van Parijs, L. et al. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity 11, 281-288 (1999).
46. Refaeli, Y., Van Parijs, L., London, C. A., Tschopp, J. & Abbas, A. K. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8, 615-623 (1998).
47. + T cells. Eur. J. Immunol. 25, 3053-3059 (1995).
48. Willerford, D. M. et al. Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3, 521-530 (1995).
49. Malek, T. R., Porter, B. O., Codias, E. K., Scibelli, P. & Yu, A. Normal lymphoid homeostasis and lack of lethal autoimmunity in mice containing mature T cells with severely impaired IL-2 receptors. J. Immunol. 164, 2905-2914 (2000).
50. Singer, G. G. & Abbas, A. K. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1, 365-371 (1994). In vivo peptide administration induces thymic deletion even in the absence of Fas signalling, but peripheral T-cell deletion is impaired.
51. Mogil, R. J. et al. Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo. Int. Immunol. 7, 1451-1458 (1995).
52. + T cells responding to a bacterial superantigen. J. Immunol. 154, 4302-4308 (1995).
53. Hildeman, D. A. et al. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity 10, 735-744 (1999).
54. Van Parijs, L., Peterson, D. A. & Abbas, A. K. The Fas/Fas ligand pathway and Bcl-2 regulate T cell responses to model self and foreign antigens. Immunity 8, 265-274 (1998).
55. Janeway, C. A. Jr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today 13, 11-16 (1992).
56. Medzhitov, R., Preston-Hurlburt, P. & Janeway, C. A. Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394-397 (1997). Cloning and characterization of a human homologue of the Drosophila Toll protein that can activate the NF-κB pathway.
57. Aderem, A. & Ulevitch, R. J. Toll-like receptors in the induction of the innate immune response. Nature 406, 782-787 (2000).
58. Poltorak, A. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085-2088 (1998).
59. Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045 (1994).
60. Basu, S., Binder, R. J., Suto, R., Anderson, K. M. & Srivastava, P. K. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway. Int. Immunol. 12, 1539-1546 (2000).
61. Kurts, C. et al. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J. Exp. Med. 184, 923-930 (1996). First demonstration of how tissue-associated antigens, which are not accessible to recirculating T cells, can be presented by bone-marrow-derived APCs to CD8 T cells in the context of MHC class I.
62. + T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J. Exp. Med. 187, 1555-1564 (1998).
63. Kurts, C., Cannarile, M., Klebba, I. & Brocker, T. Dendritic cells are sufficient to cross-present self-antigens to CD8 T cells in vivo. J. Immunol. 166, 1439-1442 (2001).
64. Hirao, M. et al. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res. 60, 2209-2217 (2000).
65. Gallucci, S., Lolkema, M. & Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nature Med. 5, 1249-1255 (1999).
66. Sauter, B. et al. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191, 423-434 (2000).
67. Huang, F. P. et al. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J. Exp. Med. 191, 435-444 (2000).
68. Inaba, K. et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J. Exp. Med. 188, 2163-2173 (1998).
69. Thery, C. et al. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein HSC 73. J. Cell. Biol. 147, 599-610 (1999).
70. Dhodapkar, M. V. Steinman, R. M., Krasovsky, J., Munz, C. & Bhardwaj, N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193, 233-238 (2001).
71. + cells from normal mice.
72. + immunoregulatory T cells is antigen nonspecific. J. Immunol. 164, 183-190 (2000).
73. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production J. Exp. Med. 186, 287-296 (1998).
74. + T functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int. Immunol. 12, 1145-1155 (2000).
75. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12, 431-440 (2000).
76. + regulatory cells that control intestinal inflammation. J. Exp. Med. 192, 295-302 (2000).
77. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192, 303-310 (2000).
78. Greenwald, R. J., Boussiotis, V. A., Lorsbach, R. B., Abbas, A. K. & Sharpe, A. H. CTLA-4 regulates induction of anergy in vivo. Immunity 14, 145-155 (2001).
79. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389, 737-742 (1997).
80. Wakkach, A., Cottrez, F. & Groux, H. Differentiation of regulatory T cells 1 is induced by CD2 costimulation. J. Immunol. 167, 3107-3113 (2001).
81. + T cells. J. Immunol. 160, 3188-3193 (1998).
82. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192, 1213-1222 (2000).
83. low cells: IL-10 and TGF-β are required for this effect.
84. Asseman, C., Mauze, S., Leach, M. W., Coffman, R. L. & Powrie, F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190, 995-1004 (1999).
85. Quinn, A. et al. Regulatory and effector CD4 T cells in nonobese diabetic mice recognize overlapping determinants on glutamic acid decarboxylase and use distinct Vβ genes. J. Immunol. 166, 2982-2991 (2001).
86. Miller, S. D. et al. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nature Med. 3, 1133-1136 (1997).
87. Zhao, Z. S., Granucci, F., Yeh, L., Schaffer, P. A. & Cantor, H. Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science 279, 1344-1347 (1998).
88. Bachmaier, K. et al. Chlamydia infections and heart disease linked through antigenic mimicry. Science 283, 1335-1339 (1999).
89. Hemmer, B. et al. Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. J. Immunol. 160, 3631-3636 (1998).
90. Hiemstra, H. S. et al. Quantitative determination of TCR cross-reactivity using peptide librades and protein databases. Eur. J. Immunol. 29, 2385-2391 (1999).
91. Steere, A. C., Gross, D., Meyer, A. L. & Huber, B. T. Autoimmune mechanisms in antibiotic treatment-resistant lyme arthritis. J. Autoimmun. 16, 263-288 (2001).
92. Gautam, A. M., Liblau, R., Chelvanayagam, G., Steinman, L. & Boston, T. A viral peptide with limited homology to a self peptide can induce clinical signs of experimental autoimmune encephalomyelitis. J. Immunol. 161, 60-64 (1998).
93. Panoutsakopoulou, V. et al. Analysis of the relationship between viral infection and autoimmune disease. Immunity 15, 137-147 (2001).
94. Keffer, J. et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025-4031 (1991).
95. Horwitz, M. S. et al. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nature Med. 4, 781-785 (1998).
96. + T cells to cause immunopathology. J. Exp. Med. 187, 763-774 (1998).
97. Shi, F. D. et al. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nature Immunol. 1, 245-251 (2000).
98. +-like thymocytes in the NOD mouse. Eur. J. Immunol. 26, 2989-2998 (1996).
99. Lehuen, A. et al. Overexpression of natural killer T cells protects Vα14-Jα281 transgenic nonobese diabetic mice against diabetes. J. Exp. Med. 188, 1831-1839 (1998).
100. Wang, B., Geng, Y. B. & Wang, C. R. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J. Exp. Med. 194, 313-320 (2001).
101. + regulatory T cells induced by an agonist self-peptide. Nature Immunol. 2, 301-306 (2001).
102. + immunoregulatory T cells. J. Exp. Med. 194, 427-438 (2001).
103. Kumanogoh, A. et al. Increased T cell autoreactivity in the absence of CD40-CD40 ligand interactions: a role of CD40 in regulatory T cell development. J. Immunol. 166, 353-360 (2001).